Compare FELE & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FELE | RNA |
|---|---|---|
| Founded | 1944 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 227.6M |
| IPO Year | 1995 | 2025 |
| Metric | FELE | RNA |
|---|---|---|
| Price | $90.96 | $13.75 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 20 |
| Target Price | ★ $103.50 | $69.26 |
| AVG Volume (30 Days) | 374.3K | ★ 2.4M |
| Earning Date | 05-20-2026 | 01-01-0001 |
| Dividend Yield | ★ 1.23% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.22 | N/A |
| Revenue | ★ $2,131,250,000.00 | N/A |
| Revenue This Year | $5.95 | $88.12 |
| Revenue Next Year | $3.94 | $18.11 |
| P/E Ratio | $28.33 | ★ N/A |
| Revenue Growth | ★ 5.44 | N/A |
| 52 Week Low | $78.88 | $13.06 |
| 52 Week High | $111.53 | $73.06 |
| Indicator | FELE | RNA |
|---|---|---|
| Relative Strength Index (RSI) | 32.46 | 5.62 |
| Support Level | $84.41 | $13.06 |
| Resistance Level | $98.40 | $72.52 |
| Average True Range (ATR) | 2.86 | 0.99 |
| MACD | -0.87 | -2.13 |
| Stochastic Oscillator | 3.97 | 1.21 |
Franklin Electric Co Inc designs, manufactures, and distributes water and fuel pumping systems, composed of submersible motors, pumps, electronic controls, water treatment systems, and related parts and equipment. It has three segments; The Water Systems segment designs, manufactures and sells motors, pumps, drives, electronic controls, monitoring devices, and related parts and equipment for use in groundwater, water transfer, and wastewater, The Energy Systems segment designs, manufactures and sells pumps, pipe, sumps, fittings, vapor recovery components, electronic controls, monitoring devices, and related parts and equipment for use in fueling system applications and the Distribution segment sells and provides presale support and specifications to the installing contractors.
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.